Active substance
Aripiprazole lauroxil
- US FDA 2
- US price lines 4
- Safety 2
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ARISTADA | 441MG/1.6ML (275.63MG/ML); 662MG/2.4ML (275.83MG/ML); 882MG/3.2ML (275.63MG/ML); 1064MG/3.9ML (272.82MG/ML) | suspension, extended release · intramuscular | ALKERMES INC | Prescription | 5 Oct 2015 |
| ARISTADA INITIO KIT | 675MG/2.4ML (281.25MG/ML) | suspension, extended release · intramuscular | ALKERMES INC | Prescription | 29 Jun 2018 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | ARISTADA ER 1,064 MG/3.9 ML SYR | $993.60013 | per ML | 23 Sep 2026 |
| US NADAC | ARISTADA ER 441 MG/1.6 ML SYRN | $1007.58949 | per ML | 23 Sep 2026 |
| US NADAC | ARISTADA ER 662 MG/2.4 ML SYRN | $1006.57422 | per ML | 23 Sep 2026 |
| US NADAC | ARISTADA ER 882 MG/3.2 ML SYRN | $1004.17967 | per ML | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 22 Jan 2025 ARISTADA — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 22 Jan 2025 ARISTADA INITIO KIT — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.